
Dr. Agarwal's Eye (DRAGARWQ) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
1.2B
Gross Profit
686.0M
58.67%
Operating Income
265.5M
22.71%
Net Income
172.6M
14.76%
EPS (Diluted)
₹36.72
Balance Sheet Metrics
Total Assets
6.1B
Total Liabilities
4.0B
Shareholders Equity
2.1B
Debt to Equity
1.93
Cash Flow Metrics
Revenue & Profitability Trend
Dr. Agarwal's Eye Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 4.0B | 3.2B | 2.7B | 2.0B | 1.4B |
Cost of Goods Sold | 1.7B | 1.3B | 1.1B | 851.5M | 646.7M |
Gross Profit | 2.3B | 1.8B | 1.5B | 1.2B | 748.9M |
Gross Margin % | 57.7% | 57.6% | 57.2% | 57.6% | 53.7% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 532.7M | 650.5M | 524.7M | 374.2M | 273.1M |
Other Operating Expenses | 574.4M | 223.5M | 215.4M | 170.9M | 147.8M |
Total Operating Expenses | 1.1B | 874.0M | 740.1M | 545.1M | 420.9M |
Operating Income | 790.5M | 677.4M | 564.7M | 382.7M | 107.7M |
Operating Margin % | 19.9% | 21.4% | 21.2% | 19.0% | 7.7% |
Non-Operating Items | |||||
Interest Income | - | 19.5M | 7.8M | 5.4M | 1.3M |
Interest Expense | 134.4M | 71.0M | 68.0M | 61.2M | 61.3M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 707.0M | 622.5M | 494.0M | 323.1M | 57.3M |
Income Tax | 160.5M | 158.9M | 124.8M | 82.1M | 71.7M |
Effective Tax Rate % | 22.7% | 25.5% | 25.3% | 25.4% | 125.1% |
Net Income | 546.5M | 463.6M | 369.2M | 241.0M | -14.4M |
Net Margin % | 13.8% | 14.6% | 13.8% | 12.0% | -1.0% |
Key Metrics | |||||
EBITDA | 1.2B | 964.0M | 765.8M | 586.0M | 298.4M |
EPS (Basic) | ₹116.28 | ₹98.64 | ₹78.55 | ₹51.29 | ₹-3.06 |
EPS (Diluted) | ₹116.28 | ₹98.64 | ₹78.55 | ₹51.29 | ₹-3.06 |
Basic Shares Outstanding | 4699862 | 4700000 | 4700000 | 4700000 | 4700000 |
Diluted Shares Outstanding | 4699862 | 4700000 | 4700000 | 4700000 | 4700000 |
Income Statement Trend
Dr. Agarwal's Eye Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 111.6M | 328.8M | 273.8M | 281.1M | 215.2M |
Short-term Investments | 158.5M | 100.0K | 28.3M | 44.6M | 69.4M |
Accounts Receivable | 139.7M | 129.3M | 101.1M | 86.7M | 87.8M |
Inventory | 134.0M | 97.5M | 60.0M | 57.3M | 52.1M |
Other Current Assets | 15.6M | 14.5M | 2.2M | 30.4M | 2.5M |
Total Current Assets | 559.4M | 598.3M | 465.4M | 500.0M | 440.7M |
Non-Current Assets | |||||
Property, Plant & Equipment | 3.7B | 1.1B | 824.3M | 649.1M | 553.6M |
Goodwill | 337.5M | 9.8M | 13.2M | 18.3M | 6.1M |
Intangible Assets | 224.3M | 6.2M | 9.6M | 14.7M | 6.1M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 143.2M | 43.3M | -100.0K | 100.0K | 7.2M |
Total Non-Current Assets | 5.6B | 4.4B | 3.4B | 2.6B | 1.1B |
Total Assets | 6.1B | 5.0B | 3.9B | 3.1B | 1.6B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 302.0M | 318.4M | 266.9M | 256.7M | 178.3M |
Short-term Debt | 275.3M | 199.7M | 187.3M | 163.3M | 190.2M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 55.1M | 21.9M | 19.9M | 18.4M | 17.2M |
Total Current Liabilities | 869.8M | 807.7M | 550.8M | 533.5M | 486.0M |
Non-Current Liabilities | |||||
Long-term Debt | 3.1B | 2.5B | 2.1B | 1.8B | 485.2M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | - | - | - | - | - |
Total Non-Current Liabilities | 3.2B | 2.6B | 2.2B | 1.8B | 519.7M |
Total Liabilities | 4.0B | 3.4B | 2.8B | 2.4B | 1.0B |
Equity | |||||
Common Stock | 47.0M | 47.0M | 47.0M | 47.0M | 47.0M |
Retained Earnings | - | 1.5B | 1.0B | 671.3M | 436.2M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 2.1B | 1.6B | 1.1B | 781.7M | 546.6M |
Key Metrics | |||||
Total Debt | 3.3B | 2.7B | 2.3B | 1.9B | 675.5M |
Working Capital | -310.4M | -209.4M | -85.4M | -33.5M | -45.3M |
Balance Sheet Composition
Dr. Agarwal's Eye Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 707.0M | 622.5M | 494.0M | 241.0M | -14.4M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -77.1M | 16.0M | 25.1M | -22.2M | -15.7M |
Operating Cash Flow | 756.1M | 673.0M | 576.5M | 279.5M | 32.1M |
Investing Activities | |||||
Capital Expenditures | 4.1M | 10.0M | 700.0K | -464.1M | -110.2M |
Acquisitions | - | - | - | - | - |
Investment Purchases | -117.5M | - | - | -249.0K | -67.0K |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -298.2M | 5.0M | -4.3M | -464.6M | -110.3M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -23.5M | -25.8M | -14.1M | -200.0K | -358.0K |
Debt Issuance | 561.8M | 150.0M | 209.4M | 257.5M | 43.2M |
Debt Repayment | -111.3M | -75.3M | -90.5M | -184.4M | -78.6M |
Financing Cash Flow | 427.0M | 48.9M | 23.7M | 64.2M | -15.1M |
Free Cash Flow | -83.8M | 184.5M | -7.2M | 99.5M | 226.9M |
Net Change in Cash | 884.9M | 726.9M | 595.9M | -120.9M | -93.3M |
Cash Flow Trend
Dr. Agarwal's Eye Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
36.63
Forward P/E
463.05
Price to Book
10.09
Price to Sales
5.11
PEG Ratio
1.64
Profitability Ratios
Profit Margin
13.96%
Operating Margin
22.71%
Return on Equity
26.07%
Return on Assets
8.91%
Financial Health
Current Ratio
0.64
Debt to Equity
158.94
Beta
-0.35
Per Share Data
EPS (TTM)
₹122.87
Book Value per Share
₹445.96
Revenue per Share
₹880.97
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
dragarwq | 21.2B | 36.63 | 10.09 | 26.07% | 13.96% | 158.94 |
Max Healthcare | 1.2T | 104.16 | 12.65 | 11.47% | 15.27% | 32.09 |
Apollo Hospitals | 1.1T | 71.43 | 13.69 | 16.71% | 6.98% | 90.89 |
Indraprastha Medical | 41.8B | 24.93 | 7.02 | 26.98% | 12.21% | 5.49 |
Shalby | 21.9B | 1,128.89 | 2.00 | 0.63% | -0.05% | 47.82 |
GPT Healthcare | 13.2B | 27.69 | 5.33 | 20.14% | 11.44% | 14.24 |
Financial data is updated regularly. All figures are in the company's reporting currency.